--- title: "Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Average sales price and wholesale acquisition cost" description: "Formulary evidence on Hibsago (bepirovirsen, GSK3228836) in Chronic hepatitis B virus infection in adults without cirrhosis: Average sales price and wholesale acquisition cost. Topics: Company statement on the timing of the U.S. list price; Royalties payable to Ionis on net sales; Japan National Health Insurance price listing, October 2026; Japan price calculation method and absence of a comparator; 4 further topics. 8 evidence topics quoted from 4 sources." canonical: "https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description/average-sales-price-and-wholesale-acquisition-cost" published: "2026-10-21T22:39:04-04:00" modified: "2026-10-22T19:07:03-04:00" --- # Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Average sales price and wholesale acquisition cost ## 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost ### Wholesale acquisition cost published at or after approval No evidence found. ### Company statement on the timing of the U.S. list price > “adding that the drug’s list price will become public once pricing and reimbursement discussions have wrapped with payers” > “We price our medicines according to the value and outcomes they bring to patients, providers and payers while being sensitive to current market and societal expectations” Source: [Fierce Pharma (2026)](https://www.fiercepharma.com/pharma/gsk-brings-promise-functional-cure-hepatitis-b-finish-line-fda-nod-hibsago) ### Royalties payable to Ionis on net sales > “Under the terms of the agreement, Ionis has received an upfront payment, license fee and development and regulatory milestone payments and is eligible to receive additional regulatory and sales milestone payments as well as tiered royalties of 10-12% on net sales of bepirovirsen.” Source: [Ionis press release, Hibsago US approval (2026)](https://ir.ionis.com/news-releases/news-release-details/ionis-partner-gsk-announces-hibsago-bepirovirsen-approved-us) ### Average sales price No evidence found. ### Japan National Health Insurance price listing, October 2026 > “新医薬品一覧表（令和８年１０月１４日収載予定）” > “ヒブサーゴ皮下注１５０ｍｇシリンジ（１５０ｍｇ１ｍＬ１筒）” > “１５０ｍｇ１ｍＬ１筒 １８３，０１５円” > “製造販売承認日 令和８年８月２４日 薬価基準収載予定日 令和８年１０月１４日” > “最初に承認された国（年月）：日本” Source: [MHLW Chuikyo new drug price listing (2026)](https://www.mhlw.go.jp/content/10808000/001756860.pdf) ### Japan price calculation method and absence of a comparator > “算定方式 原価計算方式” > “本剤の効能又は効果である「Ｂ型肝炎ウイルス持続感染における機能的治癒」の適応を有する既収載品はなく、本剤と同様の薬理作用、化学構造を有する既収載品もないことから、薬価算定上の最類似薬はないと判断した。” Source: [MHLW Chuikyo new drug price listing (2026)](https://www.mhlw.go.jp/content/10808000/001756860.pdf) ### Japan cost accounting components of the listed price per 150 mg syringe | Component | Value | |---|---| | Total product cost | “１３０，７３３円” | | Operating profit | “２４，１６４円” “（流通経費を除く価格の１５．６％）” | | Distribution cost | “１１，４８０円” “（消費税を除く価格の６．９％）” | | Consumption tax | “１６，６３８円” | | Price before and after premiums | “１８３，０１５円 → １８３，０１５円” | Source: [MHLW Chuikyo new drug price listing (2026)](https://www.mhlw.go.jp/content/10808000/001756860.pdf) ### Japan price premiums assessed and premium coefficient of zero > “補正加算 有用性加算（Ⅰ）（Ａ＝５０％）、先駆加算（Ａ＝１０％） 加算係数 ０” > “本剤はＨＢＶ由来のｍＲＮＡに結合することでタンパク質の産生を阻害するＢ型肝炎治療薬であり、既存薬とは異なる約２６年ぶりの新規作用機序医薬品であること、既存治療で効果が不十分な患者を対象とした臨床試験において、既存治療では稀であった機能的治癒の達成を認めていること等から、有用性加算（Ⅰ）（Ａ＝５０％）を適用することが適当と判断した。” > “本品は世界に先駆けて日本で承認されたものであることから、加算の要件を満たす。一方で、本剤の承認申請に係る臨床試験における日本人患者の組み入れ数は諸外国と比較し、特別優れているわけではないことから、限定的な評価とした。” Source: [MHLW Chuikyo new drug price listing (2026)](https://www.mhlw.go.jp/content/10808000/001756860.pdf) ### Japan price maintenance premium and cost-effectiveness evaluation designation > “革新的新薬薬価維持制度への該当性 該当する（主な理由：加算適用）” > “費用対効果評価への該当性該当する（Ｈ１）” Source: [MHLW Chuikyo new drug price listing (2026)](https://www.mhlw.go.jp/content/10808000/001756860.pdf) ### Japan standard drug cost per administration for inpatient DPC payment > “通常、成人にはベピロビルセンとして1回300mgを投与1週目及び2週目は3～4日毎に週2回、投与3週目以降は24週目まで週1回、皮下注射する。” > “366,030円/回” > “このほかに併用薬の費用がかかる。” > “令和８年10月14日に薬価収載を予定している医薬品等のうち以下に掲げるものは、上記基準に該当する。よって、これらの薬剤を使用した患者であって当該薬剤に対応する診断群分類に該当するものについては、次期診療報酬改定までの間、出来高算定することとしてはどうか。” Source: [MHLW Chuikyo DPC high-cost new drugs (2026)](https://www.mhlw.go.jp/content/10808000/001756861.pdf) ## Related pages - [Hibsago (bepirovirsen): Chronic hepatitis B virus infection in adults without cirrhosis](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis.md) - [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Terms and abbreviations](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/terms-and-abbreviations.md) - [Hibsago (bepirovirsen): Chronic hepatitis B virus infection in adults without cirrhosis](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/executive-summary.md) - [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Product information and disease description](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description.md) - [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Clinical evidence](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/clinical-evidence.md) - [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Economic information and modeling report](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/economics) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/economics.md) - [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: References](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/references) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/references.md) - [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: new drug review](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/monograph/review) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/monograph/review.md) - [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/cost-effectiveness-analyses.md)